SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001169245-22-000108
Filing Date
2022-10-31
Accepted
2022-10-31 17:21:13
Documents
12
Period of Report
2022-10-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K phas-20221025.htm   iXBRL 8-K 34245
  Complete submission text file 0001169245-22-000108.txt   177597

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT phas-20221025.xsd EX-101.SCH 1902
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT phas-20221025_lab.xml EX-101.LAB 25848
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT phas-20221025_pre.xml EX-101.PRE 13581
6 EXTRACTED XBRL INSTANCE DOCUMENT phas-20221025_htm.xml XML 11435
Mailing Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355
Business Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355 (610) 981-6500
PhaseBio Pharmaceuticals Inc (Filer) CIK: 0001169245 (see all company filings)

IRS No.: 030375697 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38697 | Film No.: 221347187
SIC: 2834 Pharmaceutical Preparations